Stocks › CSTL

CASTLE BIOSCIENCES INC

CSTL·Nasdaq·United States United States·USD
$32.86
-0.55 (-1.63%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
CSTL
CASTLE BIOSCIENCES INC · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
CSTLS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair

Congressional Trades

Recent trades of CSTL by members of U.S. Congress · 3 on record
All congressional trades →
PoliticianStockTypeFiledTraded
Josh GottheimerJosh GottheimerHouse · D · NJ CSTLCASTLE BIOSCIENCES INC · Stock Sale
$1,001 - $15,000
Apr 17, 2022 Mar 15, 2022 Filing ↗
Gilbert Ray Cisneros, Jr.Gilbert Ray Cisneros, Jr.House · D · CA CSTLCASTLE BIOSCIENCES INC · Stock Purchase
$1,001 - $15,000
Jan 11, 2021 Dec 23, 2020 Filing ↗
Josh GottheimerJosh GottheimerHouse · D · NJ CSTLCASTLE BIOSCIENCES INC · Stock Purchase
$1,001 - $15,000
Jan 7, 2021 Dec 21, 2020 Filing ↗

Whale Activity

Position changes in CSTL reported for 2026-09-30 by 225 institutional filers
Increased: 72New: 49Held: 18Decreased: 54Closed: 22No prior filing: 10
  • Increased72
  • New49
  • Held18
  • Decreased54
  • Closed22
  • No prior filing10
FilerSharesValueChange
BlackRock, Inc.3.5M$122.7Mincreased
RTW INVESTMENTS, LP2.8M$98.7Mheld
PRINCIPAL FINANCIAL GROUP INC1.5M$53.3M—
Portolan Capital Management, LLC1.4M$48.8Mincreased
VANGUARD CAPITAL MANAGEMENT LLC1.2M$44.0Mincreased
ACADIAN ASSET MANAGEMENT LLC881.9K$31.3Mdecreased
STATE STREET CORP804.7K$28.6Mdecreased
GEODE CAPITAL MANAGEMENT, LLC793.9K$28.2Mdecreased
VANGUARD PORTFOLIO MANAGEMENT LLC716.7K$25.5Mdecreased
DIMENSIONAL FUND ADVISORS LP692.1K$24.6Mdecreased
Jefferies Financial Group Inc.647.4K$23.0Mheld
SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC635.0K$22.6Mdecreased

Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.

Insider Trading

Net shares bought (+) or sold (−) on the open market by CSTL insiders, by quarter · Form 4
-500.0K-250.0K0250.0K500.0K2025 Q1: -71.8K2025 Q12025 Q2: -31.9K2025 Q22025 Q3: -77.7K2025 Q32025 Q4: -138.1K2025 Q42026 Q1: -150.3K2026 Q12026 Q2: -45.6K2026 Q22026 Q3: -257.7K2026 Q32026 Q4: -77.0K2026 Q4

Recent Insider Transactions

2,778 transactions on record · newest first
All insider activity →
InsiderTypeSharesPriceValueDate
MAETZOLD DEREK JPres. & Chief Exec. Officer · Director Sale −3,904 $32.92 $129K Nov 16, 2026 Form 4 ↗
MAETZOLD DEREK JPres. & Chief Exec. Officer · Director Sale −1,642 $32.92 $54K Nov 16, 2026 Form 4 ↗
MAETZOLD DEREK JPres. & Chief Exec. Officer · Director Sale −1,396 $32.92 $46K Nov 16, 2026 Form 4 ↗
Juvenal Tobin WChief Commercial Officer Sale −3,195 $35.07 $112K Nov 11, 2026 Form 4 ↗
Juvenal Tobin WChief Commercial Officer Sale −2,828 $35.04 $99K Nov 11, 2026 Form 4 ↗
Juvenal Tobin WChief Commercial Officer Sale −3,288 $32.67 $107K Nov 9, 2026 Form 4 ↗
MAETZOLD DEREK JPres. & Chief Exec. Officer · Director Sale −7,555 $36.01 $272K Nov 2, 2026 Form 4 ↗
MAETZOLD DEREK JPres. & Chief Exec. Officer · Director Sale −382 $36.81 $14K Nov 2, 2026 Form 4 ↗
MAETZOLD DEREK JPres. & Chief Exec. Officer · Director Sale −325 $36.81 $12K Nov 2, 2026 Form 4 ↗
MAETZOLD DEREK JPres. & Chief Exec. Officer · Director Sale −2,816 $36.01 $101K Nov 2, 2026 Form 4 ↗
MAETZOLD DEREK JPres. & Chief Exec. Officer · Director Sale −2,393 $36.01 $86K Nov 2, 2026 Form 4 ↗
MAETZOLD DEREK JPres. & Chief Exec. Officer · Director Sale −1,025 $36.81 $38K Nov 2, 2026 Form 4 ↗
Juvenal Tobin WChief Commercial Officer Sale −5,341 $36.62 $196K Oct 28, 2026 Form 4 ↗
Juvenal Tobin WChief Commercial Officer Sale −1,237 $35.58 $44K Oct 28, 2026 Form 4 ↗
Juvenal Tobin WChief Commercial Officer Sale −3,288 $33.08 $109K Oct 26, 2026 Form 4 ↗
MAETZOLD DEREK JPres. & Chief Exec. Officer · Director Sale −8,580 $31.91 $274K Oct 19, 2026 Form 4 ↗
MAETZOLD DEREK JPres. & Chief Exec. Officer · Director Sale −3,198 $31.91 $102K Oct 19, 2026 Form 4 ↗
MAETZOLD DEREK JPres. & Chief Exec. Officer · Director Sale −2,718 $31.91 $87K Oct 19, 2026 Form 4 ↗
Juvenal Tobin WChief Commercial Officer Sale −3,288 $33.64 $111K Oct 12, 2026 Form 4 ↗
MAETZOLD DEREK JPres. & Chief Exec. Officer · Director Sale −8,580 $35.57 $305K Oct 5, 2026 Form 4 ↗

Fund Holders

Mutual funds and ETFs holding CSTL · SEC Form N-PORT
FundSharesValue% of fundAs of
Strategic Advisers U.S. Total Stock Fund
Fidelity Rutland Square Trust II
793.4K$26.2M0.03%Aug 31, 2026
VANGUARD TOTAL STOCK MARKET INDEX FUND
VANGUARD INDEX FUNDS
852.7K$20.3M0.00%Jun 30, 2026
SmallCap Fund
Principal Funds, Inc
725.1K$20.3M0.97%Jul 31, 2026
iShares Russell 2000 ETF
iShares Trust
781.4K$18.6M0.02%Jun 30, 2026
Wasatch Micro Cap Fund
WASATCH FUNDS TRUST
276.7K$9.8M1.73%Sep 30, 2026
Fidelity Small Cap Index Fund
Fidelity Salem Street Trust
327.8K$9.2M0.03%Jul 31, 2026
Buffalo Small Cap Growth Fund
Buffalo Funds
239.6K$8.5M2.07%Sep 30, 2026
VANGUARD EXTENDED MARKET INDEX FUND
VANGUARD INDEX FUNDS
342.7K$8.2M0.01%Jun 30, 2026
VANGUARD EXPLORER FUND275.9K$7.7M0.03%Jul 31, 2026
iShares Russell 2000 Value ETF
iShares Trust
278.7K$6.6M0.05%Jun 30, 2026

Mutual funds and ETFs whose N-PORT filings list CSTL's shares (CUSIP 14843C105), each fund at its latest report since Apr 21, 2026, largest positions first. Bonds, options and short positions are left out.

Activist & Passive Stakes

Schedule 13D / 13G beneficial-ownership filings
  • PRINCIPAL GLOBAL INVESTORSSCHEDULE 13G/A · passive (13G) · 1.5M shares4.9%
    Oct 29, 2026 · ↗
  • Roderick WongSCHEDULE 13G/A · passive (13G) · 2.8M shares9.3%
    May 15, 2026 · ↗
  • RTW Investments, LPSCHEDULE 13G/A · passive (13G) · 2.8M shares9.3%
    May 15, 2026 · ↗
  • George McCabeSCHEDULE 13G/A · passive (13G) · 1.4M shares4.5%
    May 15, 2026 · ↗
  • Portolan Capital Management, LLCSCHEDULE 13G/A · passive (13G) · 1.4M shares4.5%
    May 15, 2026 · ↗

Corporate Lobbying

Estimated quarterly lobbying spending reported under the LDA, filings naming castle biosciences as client
$0$50K$100K$150K$200K2023 Q3: $30K2023 Q4: $60K20232024 Q1: $60K2024 Q2: $40K2024 Q3: $40K2024 Q4: $40K20242025 Q1: $40K2025 Q2: $40K2025 Q3: $40K2025 Q4: $40K20252026 Q1: $40K2026 Q2: $40K2026 Q3: $25K2026
  • MCDERMOTT+ LLCCASTLE BIOSCIENCES, INC. · 2026 Q3 · MMM$25K
    Filing ↗
  • MCDERMOTT+ LLCCASTLE BIOSCIENCES, INC. · 2026 Q2 · MMM$40K
    Filing ↗
  • MCDERMOTT+ LLCCASTLE BIOSCIENCES, INC. · 2026 Q1 · MMM$40K
    Filing ↗
  • MCDERMOTT+ LLCCASTLE BIOSCIENCES, INC. · 2025 Q4 · MMM$40K
    Filing ↗
  • MCDERMOTT+ LLCCASTLE BIOSCIENCES, INC. · 2025 Q3 · MMM$40K
    Filing ↗

Government Contracts

Federal awards to castle biosciences · USAspending
$167KAwarded · 2 contracts on record
  • Department of Veterans AffairsCONTRACTOR SHALL PROVIDE FOR A PREDICTIVE BARTLETT ESOPHAGUS ASSAY PBEA WHICH WILL IDENTIFY THE PROBABILITY THAT A PATIENT WILL DEVELOP ESOP$3K
    Oct 1, 2024 · ↗
  • Department of Veterans AffairsGENE EXPRESSION PROFILE TESTING$164K
    Sep 1, 2026 · ↗

U.S. Patents

Recent USPTO applications naming CASTLE BIOSCIENCES INC

No USPTO patent applications found for CASTLE BIOSCIENCES INC.

Annual Financials

From CSTL's 10-K filings · XBRL
Fiscal yearFY2025FY2024FY2023FY2022FY2021
Revenue$344.2M$332.1M$219.8M$137.0M$94.1M
Operating income-$42.8M$8.7M-$68.0M-$72.9M-$40.1M
Net income-$24.2M$18.2M-$57.5M-$67.1M-$31.3M
Diluted EPS-$0.83$0.62-$2.14-$2.58-$1.24
Operating cash flow$64.3M$64.9M-$5.6M-$41.7M-$19.0M
Cash and equivalents$116.7M$119.7M$98.8M$122.9M$329.6M
Total assets$578.6M$531.2M$453.3M$447.3M$462.6M
Total liabilities$107.7M$75.4M$62.1M$48.2M$50.8M
Shareholders' equity$470.9M$455.8M$391.3M$399.1M$411.7M

As CASTLE BIOSCIENCES INC tagged them in its 10-K filings: totals for the year on the income and cash-flow lines, values at the year's end on the balance-sheet lines. Latest 10-K, filed Feb 26, 2026 ↗

Stock Splits

Every split and reverse split in the price history

No stock splits in CSTL's price history.

Material Events (8-K)

Corporate events filed with the SEC
  • 8-K · Items 2.02, 7.01, 9.01Results of operations · Reg FD disclosureNov 5, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 7.01, 9.01Results of operations · Reg FD disclosureJul 30, 2026
    EDGAR ↗
  • 8-K · Items 5.07Shareholder voteMay 29, 2026
    EDGAR ↗
  • 8-K · Items 2.02, 7.01, 9.01Results of operations · Reg FD disclosureMay 6, 2026
    EDGAR ↗

About CASTLE BIOSCIENCES INC

From SEC EDGAR company records
Industry (SIC 8071)Services-Medical Laboratories
SectorHealthcare
HeadquartersFRIENDSWOOD, TX
IncorporatedDE